An epidemiological and intervention assessment of the malaria epidemic in Bolívar,

Background: Venezuela has experienced an explosive resurgence in Plasmodium falciparum and Plasmodium vivax malaria incidence over the last decade due to various social, political, and economic factors. To ensure national and regional progress towards malaria elimination, there is an urgent need to better understand the epidemiological dynamics of this malaria outbreak at its epicenter in the southern state of Bolivar and to identify the sets of interventions that may be necessary to reduce transmission and incidence. Methods: We fitted transmission models of P. falciparum and P. vivax to weekly incidence data in Bolivar, Venezuela during 2000-2018. We estimated the magnitude of local transmission for both Plasmodium spp. and inferred the contribution of relapses and reinfections to P. vivax incidence in the region. Compared to a business-as-usual scenario, we projected the impact of different interventions on Plasmodium spp. incidence during the period 2021-2023. Findings: We estimated that 63.7 - 73.3% of all P. vivax infections in Bolivar are relapses, leading to as many as 51,800 observed relapses misclassified per year as reinfections in the routine surveillance data. Our estimates suggest that the reproduction number remains close to one for both Plasmodium spp., pointing towards the feasibility of control. Long-lasting insecticidal nets (LLINs) were projected to cause greater proportional reductions in P. falciparum incidence than P. vivax incidence, and mass drug administration (MDA) with an 8-aminoquinoline and a blood-stage partner drug was projected to cause the greatest reduction in P. vivax incidence, provided that adherence rates were high. Interpretation: Control of the malaria outbreak in Southeastern Venezuela is feasible, should appropriate resources to support surveillance and control be brought to bear. Coupling the distribution of LLINs and a focal MDA with an 8-aminoquinoline and a blood-stage partner drug may lead to the greatest reduction in malaria incidence. Funding: National Science Foundation and the University of Notre Dame


RESEARCH IN CONTEXT
Evidence before the study: We searched PubMed, bioRxiv, and medRxiv for articles in English published on or before May 25 th , 2021 using the following keywords: "Venezuela", "malaria", AND "model*".Previous studies have applied statistical models to characterize the relationship between malaria incidence and climate in Venezuela, concluding that the reproduction number is low and suggesting the feasibility of control.A study fitting a mechanistic transmission model to epidemiological data to allow for projecting the impact of alternative approaches to control has not been performed.

Added value of the study:
We fitted Plasmodium falciparum and Plasmodium vivax transmission models to 20 years of weekly incidence data to estimate the transmission of both Plasmodium spp.and characterize the contribution of relapses and reinfections to P. vivax incidence in Bolívar, Venezuela.We also projected the likely impact of interventions in the region under alternative scenarios about control.

Implications of the available evidence:
The burden of Plasmodium vivax relapses in Bolívar is underestimated from routine surveillance data, so control interventions must target the hypnozoite reservoir in the region.Mass drug administration (MDA) is projected to be impactful for both Plasmodium spp., though tradeoffs between coverage and adherence suggest that a focal MDA with an 8-aminoquinoline and a blood-stage partner drug may yield the greatest impact.

INTRODUCTION
8] Efforts to address the malaria resurgence in Venezuela are urgently needed to ensure that the WHO Region of the Americas meets the targets established by the Global Technical Strategy for Malaria, 2016-2030. 1Recently, the Global Fund to Fight AIDS, Tuberculosis, and Malaria approved Venezuela to receive additional funding to expand malaria control efforts. 9To achieve the greatest impact, the selection of interventions as part of this expansion should be guided by the local epidemiological dynamics in Bolívar, the epicenter of the malaria resurgence.
In an area with co-circulation of P. vivax and P. falciparum, the immediate impacts of interventions, such as long-lasting insecticidal nets (LLINs) and mass drug administration (MDA), on malaria incidence depend upon the extent to which P. vivax infections are reinfections caused by mosquito biting or relapses caused by hypnozoite activation.If most P. vivax infections are reinfections, then interventions that can achieve reductions in P. falciparum burden, such as LLINs, will likely be effective in reducing P. vivax burden, too.By contrast, if most P. vivax infections are relapses, then interventions that target the hypnozoite reservoir, such as MDA with an 8-aminoquinoline, may be needed.
Disentangling the contributions of reinfections and relapses to P. vivax burden in Bolívar using epidemiological data alone is challenging, because reinfections and relapses cannot be easily .distinguished using standard diagnostic criteria.Fitting mathematical models-that explicitly account for both transmission dynamics and the possibility of diagnostic errors-to epidemiological data is an advantageous approach to both characterize the nature of the local malaria burden and inform the best approaches to control. 10this modelling study, we fitted mechanistic models of P. falciparum and P. vivax transmission to epidemiological data collected in Bolívar, Venezuela during 2000-2018.We first analyzed changes in the epidemiological dynamics of P. falciparum and P. vivax over the same time period using the fitted models and then projected the likely impact of interventions in the region under alternative scenarios about control.

Malaria Transmission Models
We developed deterministic compartment models to characterize the transmission dynamics of P. falciparum and P. vivax malaria in Bolívar, Venezuela.To account for changes in transmission over time, the models used a time-varying form of the reproduction number derived from first principles of transmission, which calculates the expected number of secondary infections arising from each infected individual. 11By treating the reproduction number as timevarying, we accounted for the effects of temporal variation in mosquito and parasite traits on transmission [12][13][14] and were able to model the effects of interventions on each component of the transmission cycle. 10,15the P. falciparum model, individuals are initially susceptible and are then infected according to the time-varying reproduction number.Following infection, a proportion of individuals seek treatment with artemisinin combination therapy (ACT) in a health clinic, and the remaining .proportion of individuals are untreated and clear their infection naturally.In Venezuela, the firstline ACT used is Artemether-Lumefantrine (AL).To model ACT adherence, we assumed that a proportion of treated individuals adhere fully to ACT and clear the P. falciparum infection.The remaining proportion of treated individuals were non-adherent to ACT and experienced a recrudescing infection.The duration of a P. falciparum infection depended upon whether an individual received ACT and was generated using a within-host model from Johnston et al. 13,14 Following clearance of the infection, individuals enter into a recovered state, where they experience a period of temporary immunity that is exponentially distributed.
The P. vivax model is structurally similar to the P. falciparum transmission model, though it accounts for the latent, liver-stage P. vivax parasites, known as hypnozoites, which can cause relapsing infections.Initially, individuals are susceptible and free from hypnozoites and are infected according to the time-varying reproduction number.We assumed that each P. vivax infection resulted in both a primary bloodstream infection and a latent liver infection with hypnozoites.As was modeled in the P. falciparum transmission model, a proportion of individuals seek treatment with chloroquine (CQ) in a health clinic, and a proportion of treated individuals also receive radical cure with primaquine (PQ).Depending upon the treatment regimen, treatment of a P. vivax infection could result in one of two outcomes: (1) complete clearance of the primary bloodstream and latent liver infections or (2) clearance of the primary bloodstream infection only.Untreated individuals were assumed to clear only the primary bloodstream infection.Following clearance of the bloodstream infection, individuals with hypnozoites could relapse or become re-infected.Upon clearance of both primary bloodstream and latent liver infections, all individuals enter into a recovered state, where they experience a .period of temporary immunity that is exponentially distributed.Following loss of immunity, individuals are once again susceptible and can be re-infected.
In both transmission models, we accounted for changes in the population through births and deaths. 16We did not model movement within Bolívar, nor did we address heterogeneity in transmission risk.Further details of the P. falciparum and P. vivax transmission models are provided in the appendix.

Intervention Models
We modeled the impact of long-lasting insecticidal nets (LLIN) and mass drug administration (MDA) compared to the existing standard of care for clinical episodes of P. falciparum and P. vivax.
An increase in LLIN coverage was assumed to impact P. falciparum and P. vivax transmission through a reduction in mosquito biting, an increase in mosquito mortality, and a corresponding reduction in the mosquito population. 15We modeled reductions in LLIN usage and insecticidal activity over time and assumed that the mean durations of LLIN usage and insecticidal activity were 84•2 and 130 weeks, respectively. 10A supplementary analysis was performed to evaluate the sensitivity of the projected impact to the assumed parameter values.
The effect of MDA on P. falciparum and P. vivax transmission depended upon the antimalarial drugs included.Treatment with ACT was assumed to clear both P. falciparum and P. vivax bloodstream infections and, by default, provided three weeks of prophylaxis.We assumed that treatment with CQ cleared P. vivax bloodstream infections and, by default, provided two weeks of prophylaxis.Only radical cure with PQ could clear the latent liver-stage P. vivax infection, and adherence to PQ was assumed to be 100% at baseline.For all MDA campaigns, we calculated the effective coverage from a target coverage by accounting for contraindications due to pregnancy and G6PD status.A complete description of all interventions can be found in the appendix.

Model Fitting
We used weekly incidence data during 2000-2018 and cumulative incidence data during 2018-2019 reported by the Venezuelan Ministry of Health as well as annual prevalence estimates generated by the Malaria Atlas Project during 2000-2017. 17To obtain a counterfactual against which our impact projections were evaluated, we produced forward simulations of the transmission models during 2021-2023.
We fitted our P. falciparum and P. vivax transmission models to the epidemiological data using a Bayesian framework.To account for spatial heterogeneity within Bolívar that could affect impact projections, we similarly re-fitted our transmission models to data from the Sifontes municipality, the epicenter of the malaria epidemic within Bolívar.A full description of the model-fitting procedure, as well as the parameters estimated during model fitting, are provided in the appendix.

Scenario Analyses
We projected the impact of alternative intervention packages on P. falciparum and P. vivax transmission in Bolívar.The intervention packages considered beyond the existing standard of care were distribution of LLINs and the implementation of MDA.
All intervention packages were assumed to be implemented at the start of 2021.For LLIN distribution, we varied the coverage from 10-90% in increments of 10%.For MDA, we varied .the coverage from 50-80% in increments of 5%.We also varied the choice of antimalarial drugs and the assumed level of adherence.These settings were assumed to apply consistently throughout the intervention period.
We calculated the absolute reduction and the percent reduction in P. falciparum and P. vivax incidence during 2021-2023 for each intervention package relative to a business-as-usual scenario.Full details of the implementation of the intervention packages are provided in the appendix.

RESULTS
The fitted transmission models captured the long-term changes and seasonal fluctuations therein in P. falciparum and P. vivax incidence in Bolívar (Fig. 1).We estimated that P. falciparum incidence increased over the period 2000-2018 and then decreased during 2019-2020 and that P. vivax incidence increased over the period 2000-2020.The estimated divergent trajectories in P. falciparum and P. vivax incidence matched the stable cumulative Plasmodium spp.incidence from 2018 to 2019, the time period for which complete weekly incidence data were not available (Fig. S10A).Furthermore, our estimates of annual P. vivax prevalence during 2000-2017 were consistent with the increase in predicted geospatial prevalence estimates to which the transmission model was fitted (Fig. S10B). .

Figure 1. Comparison of fitted transmission model to weekly epidemiological data. The fitted P. falciparum and P. vivax transmission models are compared to the weekly incidence data for (A) reported P. falciparum new infections, (B) reported P. vivax new infections, (C) reported P. falciparum recrudescing infections, and (D) reported P. vivax relapses. The shaded gray area represents the period for which weekly incidence data was available, and each gray point is the reported incidence in a given week. The colored line is the median posterior estimate from the fitted transmission model, and the colored shaded region is the 95% posterior prediction interval.
Weekly Incidence (2000−2018)    (Fig. 2C).This difference between the epidemiological data and the estimated transmission dynamics was explained by the large number of relapses that we inferred to have been misclassified as new infections.We estimated that in 2018 the annual number of relapses that were misclassified as new infections was 32,500 (95% PPI: 14,500 -61,400), while the annual number of new infections that were misclassified as relapses was only 52 (0 -189) (Fig. 2B).
We also examined changes in the transmission dynamics during 2000-2020.We estimated that the reproduction numbers for both Plasmodium spp.have remained close to one over the time period considered (Fig. 2A), though seasonal fluctuations were estimated to cause transmission to peak around the second-to-last week of April in each year.That the reproduction numbers have remained close to one indicated the feasibility of control should interventions be implemented.Nevertheless, estimating transmission at the state level may obscure important heterogeneity in transmission risk, and transmission models fitted to the Sifontes municipality, the epicenter of the outbreak in Bolívar, revealed a potentially higher level of transmission of P.

B Misclassified Relapses Misclassified New Infections Misclassified Relapses
Misclassified New Infections .
Under an alternative scenario with a target coverage of 90%, we projected that the distribution of LLINs would avert 56,400 (52,500 -59,400) P. falciparum infections and 1.03 million (1.02 -1.04 million) P. vivax infections over the time period 2021-2023.When measured as proportional reduction in incidence relative to a business-as-usual scenario, the distribution of LLINs is expected to be more impactful for P. falciparum than P. vivax at all target coverages considered (Fig. 3B).The diminished projected impact of LLINs for P. vivax relative to P.
falciparum was attributed to the high proportion of relapsing infections (Fig. 2C), which are not prevented by the use of LLINs.Adherence to treatment is assumed to be 100%.In both plots, the height of the bar denotes the median of the posterior prediction distribution, and the segments are the 95% posterior prediction interval.
Our projected impact of MDA with radical cure assumed, by default, complete adherence to PQ. Primaquine adherence, however, is low given the length of treatment, and measures taken to ensure high rates of adherence may be operationally infeasible at the target coverages considered.We therefore examined how our impact projections varied as a function of MDA coverage and PQ adherence.We found that the expected impact of MDA with CQ + PQ depended upon the assumed PQ adherence.At a target coverage of 50%, the expected reduction in P. vivax infections ranged from 49% at 0% PQ adherence to 60% at 100% PQ adherence (Fig. 6B).By contrast, at 50% PQ adherence, increasing the target coverage from 50% to 80% increased the expected reduction in P. vivax infections from 55% to 70%.Our results suggest that comparable projected impacts on P. vivax can be achieved under both low coverage, high adherence and high coverage, low adherence scenarios.Focal MDA that targets a smaller subset of the population at higher risk of exposure to P. vivax and ensures high PQ adherence may be preferred to an intervention strategy that maximizes the target coverage.We projected that the distribution of LLINs in Bolívar would cause a greater proportional reduction in P. falciparum infections than P. vivax infections.The reduced impact on P. vivax occurred because most P. vivax infections were inferred to be relapses, not reinfections.
Although LLINs can prevent onward transmission arising from relapses, they do not reduce the reservoir of hypnozoites acquired prior to intervention allocation.Therefore, short-term reductions in burden will be less for P. vivax than for P. falciparum, consistent with observations from a longitudinal study in Papua New Guinea. 18 Relative to LLINs, MDA was projected to yield proportional reductions in incidence that were more comparable across Plasmodium spp.Increasing the duration of prophylaxis of the antimalarial drug provided a greater benefit for P. falciparum than P. vivax, because most P.
vivax infections were caused by relapse, not reinfection.MDA that included an 8aminoquinoline, such as PQ, is expected to cause a large reduction in P. vivax incidence by targeting the hypnozoite reservoir.Therefore, MDA that combines an antimalarial drug with a long duration of prophylaxis, such as dihydroartemisinin-piperaquine, and an 8-aminoquinoline, such as primaquine, to clear the hypnozoites may be an appropriate strategy to jointly address the burden of P. falciparum and P. vivax.
Our projected impact of MDA with PQ on the P. vivax burden in Bolívar revealed a tradeoff between the target coverage and the assumed level of PQ adherence.Low coverage scenarios with high PQ adherence were projected to have comparable levels of impact to high coverage scenarios with low PQ adherence, highlighting a potential role for focal MDA in Bolívar.With a lower target coverage, a focal MDA could ensure high rates of adherence among certain demographics at high risk of infection, such as gold miners, thereby addressing the large hypnozoite reservoir in the region. 6,8Success of focal MDA targeting individuals with occupational hazard of Plasmodium spp.infection was recently documented in a nearelimination setting in Costa Rica. 19 limited data on Plasmodium spp.prevalence and historical intervention use in the region could have affected our inferences and the resultant impact projections.Due to a lack of recent prevalence surveys in Bolívar, we calibrated our transmission models to weekly incidence data and geospatial P. vivax prevalence estimates from Battle and colleagues. 17Incidence data, however, is subject to issues of reporting and likely does not capture asymptomatic and low-.density infections. 20The geospatial prevalence estimates are modelled quantities themselves and therefore must be interpreted with caution.Moreover, data on historical LLIN coverage was limited, which may have caused us to underestimate LLIN usage in the region and thus underestimate the time-varying reproduction numbers.Data on LLIN distribution during 2018-2019 was not available, though the increase in LLIN usage may help to explain the decline in transmission captured for P. falciparum in recent years.By potentially underestimating the reproduction numbers, we may also be overestimating the impact of interventions, so our projections should be considered as an upper bound of potential impact.Finally, we assumed that efficacy of CQ against P. vivax infection was high in Bolívar, so reduced efficacy on account of CQ resistance or poor adherence may reduce the impact of MDA.Nevertheless, we expect that the general relationships among intervention impact and target coverage, duration of prophylaxis, and assumed level of adherence should hold true.
Future intervention analyses in Bolívar would benefit from examining impact at finer spatial scales and accounting for ongoing demographic changes in this area.Transmission models calibrated at the municipality or parish levels could capture greater spatial heterogeneity in transmission risk 21 and could be extended to realistically model the movement of hosts and parasites across administrative boundaries. 22Extending the framework developed in this analysis to accommodate finer spatial scales would continue efforts toward precision public health by providing policy makers with a model-and data-driven selection of targeted interventions to address the malaria epidemic in Venezuela. 23

Figure 3 .
Figure 3. Projected impact of LLIN distribution during 2021-2023.(A) The expected number of

Figure 4 .
Figure 4. Projected impact of MDA (CQ vs. ACT) during 2021-2023.(A) The expected number transmission.Nevertheless, our results underscore the potential impact of radical in MDA campaigns on the hypnozoite reservoir in Bolívar.

Figure 6 .A
Figure 6.Effect of coverage and adherence on the projected impact of MDA (CQ + PQ) for P.
The epidemiological dynamics of the fitted P. vivax transmission model indicated that the epidemiological data may have underestimated the extent of relapsing infections in Bolívar.On the basis of the epidemiological data alone, the annual proportion of P. vivax cases that were